Effects of an HMG-CoA reductase inhibitor, simvastatin, on human myeloma cells

Oncology Reports

Volumn 11, Issue 5, 2004, Pages 1053-1058

  Otsuki, Takemi ^a   Sakaguchi, Haruko ^a   Hatayama, Tamayo ^a   Fujii, Tomohiro ^a   Tsujioka, Takayuki ^a   Sugihara, Takashi ^a   Takata, Akiko ^a   Hyodoh, Fuminori ^a   Eto, Masaaki ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Anti oxides; Apoptosis; HMG CoA reductase inhibitor (statin); MAP kinase; Myeloma

Indexed keywords

ALPHA INTERFERON; ANTIOXIDANT; DEXAMETHASONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAP2K1 PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; RETINOIC ACID; SIMVASTATIN; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CELL DIVISION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METABOLISM; MULTIPLE MYELOMA; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIOXIDANTS; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; DEXAMETHASONE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERFERON-ALPHA; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MAP KINASE KINASE 4; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MULTIPLE MYELOMA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; SIMVASTATIN; TRETINOIN;

EID: 16544368557     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.5.1053     Document Type: Article

References (37)

1. Lauta VM: A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 97: 2440-2452, 2003.
2. Kumar A, Loughran T, Alsina M, Durie BG and Djulbegovic B: Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol 4: 293-304, 2003. (Pubitemid 36592497)
3. Drach J and Kaufmann H: New developments and treatment in multiple myeloma: new insights on molecular biology. Ann Oncol 13 (Suppl 4): 43-47, 2002. (Pubitemid 35363752)
4. Raje N and Anderson KC: Multiple myeloma. Curr Treat Options Oncol 1: 73-82, 2000.
5. Munshi NC, Barlogie B, Desikan KR and Wilson C: Novel approaches in myeloma therapy. Semin Oncol 26 (Suppl 13): 28-34, 1999. (Pubitemid 29483269)
6. Major PP and Cook R: Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol 25 (Suppl 1): S10-S18, 2002. (Pubitemid 35476854)
7. Jantunen E: Bisphosphonate therapy in multiple myeloma: past, present, future. Eur J Haematol 69: 257-264, 2002.
8. Yata K, Otsuki T, Yamada O, Wada H, Yawata Y and Sugihara T: Synergistic growth inhibition of YM529 with biologic response modifiers (BRMs) in myeloma cells. Int J Hematol 75: 534-539, 2002.
9. Kirkwood J: Cancer immunotherapy: the interferon-alpha experience. Semin Oncol 29 (Suppl 7): 18-26, 2002.
10. Ezaki K: Cytokine therapy for hematological malignancies. Int J Hematol 65: 17-29, 1996.
11. Cheng-Lai A: Related rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. Heart Dis 5: 72-78, 2003.
12. Bonetti PO, Lerman LO, Napoli C and Lerman A: Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J 24: 225-248, 2003. (Pubitemid 36207079)
13. Ballantyne CM: Familial hypercholesterolaemia: optimum treatment strategies. Int J Clin Pract 130: S22-S26, 2002.
14. McKenney JM: New cholesterol guidelines, new treatment challenges. Pharmacotherapy 22: 853-863, 2002.
15. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y and Matsuzawa Y: Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 84: 886-891, 2001. (Pubitemid 32385829)
16. Rao S, Porter DC, Chen X, Herliczek T, Lowe M and Keyomarsi K: Lovastatin-mediated Gl arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA 96: 7797-7802, 1999. (Pubitemid 29328361)
17. Vitols S, Angelin B and Juliusson G: Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans - in vitro and in vivo studies. Lipids 32: 255-262, 1997. (Pubitemid 27131758)
18. Newman A, Clutterbuck RD, Powles RL, Catovsky D and Millar JL: A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Leuk Lymphoma 24: 533-537, 1997. (Pubitemid 27182208)
19. Narisawa T, Morotomi M, Fukaura Y, Hasebe M, Ito M and Aizawa R: Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 87: 798-804, 1996. (Pubitemid 26335806)
20. Gebhardt A and Niendorf A: Effects of pravastatin, a hydroxy- methylglutaryl-CoA reductase inhibitor, on two human tumour cell lines. J Cancer Res Clin Oncol 121: 343-349, 1995.
21. Van de Donk NW, Kamphuis MM, Lokhorst HM and Bloem AC: The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 16: 1362-1371, 2002.
22. Eto M, Kozai T, Cosentino F, Joch H and Luscher TF: Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 105: 1756-1759, 2002. (Pubitemid 34408880)
23. Horiuchi M, Cui TX, Li Z, Li JM, Nakagami H and Iwai M: Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation 107: 106-112, 2003. (Pubitemid 36070941)
24. Gueler F, Rong S, Park JK, Fiebeler A, Menne J, Elger M, Mueller DN, Hampich F, Dechend R, Kunter U, Luft FC and Haller H: Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J Am Soc Nephrol 13: 2288-2298, 2002. (Pubitemid 34925239)
25. Chung HK, Lee IK, Kang H, Suh JM, Kim H, Park KC, Kim DW, Kim YK, Ro HK and Shong M: Statin inhibits interferon-gammag-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp Mol Med 34: 451-461, 2002. (Pubitemid 36114363)
26. Otsuki T, Yata K, Sakaguchi H, Uno M, Fujii T, Wada H, Sugihara T and Ueki A: IL-10 in myeloma cells. Leuk Lymphoma 43: 969-974, 2002. (Pubitemid 34460878)
27. Otsuki T, Yamada O, Kurebayashi J, Moriya T, Sakaguchi H, Kunisue H, Yata K, Uno M, Yawata Y and Ueki A: Estrogen receptors in human myeloma cells. Cancer Res 60: 1434-1441, 2000. (Pubitemid 30152018)
28. Otsuki T, Hata H, Harada N, Matsuzaki H, Yata K, Wada H, Yawata Y, Ueki A and Yamada O: Cellular biological differences between human myeloma cell lines KMS-12-PE and KMS-12-BM established from a single patient. Int J Hematol 72: 216-222, 2000.
29. Uno M, Otsuki T, Kurebayashi J, Sakaguchi H, Isozaki Y, Ueki A, Yata K, Fujii T, Hiratsuka J, Akisada T, Harada T and Imajo Y: Anti-HER2-antibody enhances irradiation-induced growth inhibition in head and neck carcinoma. Int J Cancer 94: 474-479 2001. (Pubitemid 32979536)
30. Ueda S, Masutani H, Nakamura H, Tanaka T, Ueno M and Yodoi J: Redox control of cell death. Antioxid Redox Signal 4: 405-414, 2002. (Pubitemid 34753380)
31. Otsuki T, Yata K, Sakaguchi H, Kurebayashi J, Matsuo Y, Uno M, Fujii T, Eda S, Isozaki Y, Yawata Y, Yamada O, Wada H, Sugihara T and Ueki A: Interleukin 10 abolishes the growth inhibitory effects of all-trans retinoic acid on human myeloma cells. Br J Haematol 116: 787-795, 2002. (Pubitemid 34226997)
32. Otsuki T, Sakaguchi H, Hatayama T, Wu P, Takata A and Hyodoh F: Effects of all-trans retinoic acid (ATRA) on human myeloma cells. Leuk Lymphoma 44: 1651-1656, 2003. (Pubitemid 37221037)
33. Puthier D, Bataille R and Amiot M: IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 29: 3945-3950, 1999.
34. Hideshima T, Akiyama M, Hayashi T, Richardson P, Schlossman R, Chauhan D and Anderson KC: Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 101: 703-705, 2003. (Pubitemid 36077596)
35. Dai Y, Landowski TH, Rosen ST, Dent P and Grant S: Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and - resistant myeloma cells through an IL-6-independent mechanism. Blood 100: 3333-3343, 2002. (Pubitemid 35217085)
36. Zhang B and Fenton RG: Proliferation of IL-6-independent multiple myeloma does not require the activity of extracellular signal-regulated kinases (ERK1/2). J Cell Physiol 193: 42-54, 2002. (Pubitemid 34969127)
37. Lin A: Activation of the JNK signaling pathway: breaking the brake on apoptosis. Bioessays 25: 17-24, 2003.